Reducing Topical Mometasone Furoate Doses by Applying Hyaluronic Acid as a Skin Penetration Enhancer

Usama Farghaly Aly

Authors

Usama Farghaly Aly

Keywords:

hyaluronic acid, mometasone furoate, topical, rheology, release, anti-inflammatory, dose

Abstract

The objective of the present study was to investigate the possibility to add hyaluronic acid (HA) as skin penetration enhancer to mometasone furoate (MF) to enhance its skin absorption, and so decrease the dose and side effects in different types of topical formulations including absorption ointment base, oil in water emulsion base and water in oil emulsion base in addition to alcoholic gel base. MF was introduced into the bases with and without the addition of 0.1% HA. The prepared formulations were evaluated for physical appearance, rheological behavior, drug release through a standard cellophane membrane and antiinflammatory effects in carrageenan-induced oedema in male albino rats. Results showed that all formulations showed good and acceptable physical properties. The in-vitro release rate of each base and its corresponding one, with 0.1% HA, showed no statistical differences.

Downloads

How to Cite

Reducing Topical Mometasone Furoate Doses by Applying Hyaluronic Acid as a Skin Penetration Enhancer. (2014). Global Journal of Medical Research, 14(38), 13-23. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

I. Aml, M. Fathy, Sohair el-shanawany (2013) Study of fluconazole release from o/w cream and water soluble ointment bases. 3(4), 686-696.

Barbucci R, Lampeni S, Barzacchiello A, Ambrosio L, Fini M, Torricelli P, Giardino R (2002) Hyaluronic acid hydrogel in the treatment of osteoarthritis. 23(23), 4503-4513. https://doi.org/10.1016/s0142-9612(02)00194-1

J. Bousquet (2009) Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. 63(5), 806-819.

M. Brown, S. Jones (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. 19(3), 308-318. https://doi.org/10.1111/j.1468-3083.2004.01180.x

Chi S, Jun H (1991) Release rate of ketoprofen from poloxamer gel in a membranous diffusion cell. 80(3), 280-283.

Hoogstrate AJ, Verohoef J (1991) Kinetic intrastructural aspects and molecular modeling of transdermal peptide flux enhancement by Nalkylazocylo heptan. 76, 37-47.

Howard Maibach, A. Kligman (1962) The Biology of Experimental Human Cutaneous Moniliasis (Candida Albicans). 85(2), 233. https://doi.org/10.1001/archderm.1962.01590020073009

P. Sandhu, A. Bilandi, S. Kumar, B. Kapoor, S. Kataria, D. Rathore, S. Bhardwaj (2012) Additives in topical dosage forms. Int J Pharml. 2(1), 78-96.

J. Tracey, A. Dine, T. Robert (1999) AnAbsorption of hyaluronan applied to the surface of intact skin. 113, 740-746.

Warner M, Camisa C (2001) Topical corticosteroids. 27, 548-577.

Wester RC, Maibach HI (1991) 4, 75-96.

Stephen Wolverton (2001) Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. 562-563.

Stephen Wolverton (2001) Comprehensive Dermatologic Drug Therapy.